MX2024012316A - Composiciones y metodos para el tratamiento de cancer solido - Google Patents

Composiciones y metodos para el tratamiento de cancer solido

Info

Publication number
MX2024012316A
MX2024012316A MX2024012316A MX2024012316A MX2024012316A MX 2024012316 A MX2024012316 A MX 2024012316A MX 2024012316 A MX2024012316 A MX 2024012316A MX 2024012316 A MX2024012316 A MX 2024012316A MX 2024012316 A MX2024012316 A MX 2024012316A
Authority
MX
Mexico
Prior art keywords
compositions
methods
solid cancer
treating solid
treating
Prior art date
Application number
MX2024012316A
Other languages
English (en)
Spanish (es)
Inventor
Robert C Allen
Jr Jackson T Stephens
Original Assignee
Exoxemis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exoxemis Inc filed Critical Exoxemis Inc
Publication of MX2024012316A publication Critical patent/MX2024012316A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03004—Glucose oxidase (1.1.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024012316A 2022-04-13 2024-10-04 Composiciones y metodos para el tratamiento de cancer solido MX2024012316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263330553P 2022-04-13 2022-04-13
PCT/US2023/018289 WO2023200842A1 (en) 2022-04-13 2023-04-12 Compositions and methods for treating solid cancer

Publications (1)

Publication Number Publication Date
MX2024012316A true MX2024012316A (es) 2024-11-08

Family

ID=88330172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012316A MX2024012316A (es) 2022-04-13 2024-10-04 Composiciones y metodos para el tratamiento de cancer solido

Country Status (10)

Country Link
US (1) US20250332226A1 (https=)
EP (1) EP4507793A1 (https=)
JP (1) JP2025512366A (https=)
KR (1) KR20250004257A (https=)
CN (1) CN119677528A (https=)
AU (1) AU2023252830A1 (https=)
CA (1) CA3246603A1 (https=)
IL (1) IL316053A (https=)
MX (1) MX2024012316A (https=)
WO (1) WO2023200842A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486408A (en) * 1981-04-07 1984-12-04 Kiel Johnathan L Insoluble crosslinked cytotoxic oxidase-peroxidase system
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition
WO2013009910A2 (en) * 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
WO2021202592A2 (en) * 2020-03-30 2021-10-07 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
CA3196357A1 (en) * 2020-11-11 2022-05-19 Robert C. Allen Compositions and methods for treating solid cancer

Also Published As

Publication number Publication date
EP4507793A1 (en) 2025-02-19
AU2023252830A1 (en) 2024-10-10
IL316053A (en) 2024-11-01
WO2023200842A1 (en) 2023-10-19
CN119677528A (zh) 2025-03-21
KR20250004257A (ko) 2025-01-07
US20250332226A1 (en) 2025-10-30
JP2025512366A (ja) 2025-04-17
CA3246603A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
MX2024005228A (es) Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
WO2023287730A8 (en) Tricyclic compounds
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
CR20240296A (es) Inhibidores parp1
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
MX2022008099A (es) Tratamiento para el cancer con inhibidores de cdk12/13.
MX2024014830A (es) Compuestos de degradacion de wee1 y usos de los mismos
MX2025000552A (es) Conjugados anticuerpo-fármaco
WO2021038296A3 (en) Modified tff2 polypeptides
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
WO2022261183A3 (en) Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2024006292A3 (en) Methods of treating cancer
WO2024163641A3 (en) Formulations for treating cancer
MX2023006087A (es) Formulaciones liofilizadas de tegavivint.
WO2022036065A3 (en) Compositions and methods for treating cancers
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
MX2023005171A (es) Composiciones y metodos para tratamiento de cancer solido.
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
WO2023019186A3 (en) Compositions and methods for treatment of cancer
WO2019190927A3 (en) Splice-switching oligonucleotides and methods of use
WO2021178960A3 (en) Compositions and methods for treatment of cancer